Business
Growth & Innovation Forum 2020
Growth & Innovation Forum 2020.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 1275C Creo Medical Group PLC 06 February 2020 \n\nCreo Medical Group plc\n(\"Creo\" or the \"Company\")\n \nGrowth & Innovation Forum 2020\n \nCreo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it will be exhibiting at the Growth & Innovation Forum 2020 on Tuesday 11 February at the Business Design Centre, London N1. \n \nMembers of the CREO team will be at stand 2 throughout the day and Prof. Chris Hancock, CTO, will be presenting at 10.05am in the Babbage room.\n \nThis is a one-day investor event exhibiting companies focused on growth and technology, attracting both institutional and retail investors. For further information, please visit the event website at:\nhttps://www.sharesmagazine.co.uk/events/event/growth-innovation-forum-2020-1\n \nThe presentation will be available on the Company website shortly after the event here: https://investors.creomedical.com/investors/reports-and-presentations/2019\n \nIf you are interested in attending the presentation and would like information on how to register, please contact Walbrook PR at [email protected] \n \nNo new material information will be disclosed at the event.\n \n For further information, please contact:\n \n\n\n\nCreo Medical Group plc\n\n\n \n\n\n\n\nRichard Rees (CFO)\n\n\n+44 (0)129 160 6005 \n\n\n\n\n \n\n\n \n\n\n\n\nCenkos Securities\n\n\n+44 (0)20 7397 8900\n\n\n\n\nStephen Keys/Mark Connelly (NOMAD)\n\n\n \n\n\n\n\nMichael Johnson / Russell Kerr (Sales)\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nWalbrook PR Ltd\n\n\n+44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\n+44 (0)7980 541 893\n\n\n\n \n \nAbout Creo Medical\n \nCreo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides ...